Sunesis Pharmaceuticals (NASDAQ: [[ticker:SNSS]]), the South San Francisco-based drug developer, said today it has raised $15.5 million in a new securities offering. The deal consists of shares of common stock and warrants to buy stock, Sunesis said. The cash will be used for the company’s pivotal clinical trial of vosaroxin, in combination with chemotherapy, for patients with relapsed forms of acute myeloid leukemia.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
